Onsdag 2 Juli | 02:09:07 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2026-02-12 07:50 Bokslutskommuniké 2025
2025-11-07 07:50 Kvartalsrapport 2025-Q3
2025-08-08 07:50 Kvartalsrapport 2025-Q2
2025-05-23 - X-dag ordinarie utdelning RAY B 3.00 SEK
2025-05-22 - Årsstämma
2025-05-09 - Kvartalsrapport 2025-Q1
2025-02-21 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-16 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag bonusutdelning RAY B 1.3
2024-05-23 - X-dag ordinarie utdelning RAY B 0.70 SEK
2024-05-22 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-02-23 - Bokslutskommuniké 2023
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning RAY B 0.00 SEK
2023-05-25 - Årsstämma
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-28 - Bokslutskommuniké 2022
2022-11-29 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-27 - X-dag ordinarie utdelning RAY B 0.00 SEK
2022-05-25 - Årsstämma
2022-05-18 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning RAY B 0.00 SEK
2021-05-26 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-23 - Bokslutskommuniké 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-07-01 - X-dag ordinarie utdelning RAY B 0.00 SEK
2020-06-30 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-05-22 - X-dag ordinarie utdelning RAY B 0.00 SEK
2019-05-21 - Årsstämma
2019-05-09 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning RAY B 0.00 SEK
2018-05-29 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017
2017-11-22 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-24 - X-dag ordinarie utdelning RAY B 0.00 SEK
2017-05-23 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1
2017-02-17 - Bokslutskommuniké 2016
2016-11-18 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-18 - X-dag ordinarie utdelning RAY B 0.25 SEK
2016-05-17 - Årsstämma
2016-05-12 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-11-25 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-05-29 - X-dag ordinarie utdelning RAY B 0.00 SEK
2015-05-28 - Årsstämma
2015-05-08 - Kvartalsrapport 2015-Q1
2015-02-12 - Bokslutskommuniké 2014
2014-11-27 - Kvartalsrapport 2014-Q3
2014-08-27 - Kvartalsrapport 2014-Q2
2014-05-28 - X-dag ordinarie utdelning RAY B 0.00 SEK
2014-05-27 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-13 - Bokslutskommuniké 2013
2013-11-27 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-05-23 - X-dag ordinarie utdelning RAY B 0.00 SEK
2013-05-22 - Årsstämma
2013-05-16 - Kvartalsrapport 2013-Q1
2013-02-14 - Bokslutskommuniké 2012
2012-11-16 - Kvartalsrapport 2012-Q3
2012-08-28 - Kvartalsrapport 2012-Q2
2012-05-31 - X-dag ordinarie utdelning RAY B 0.00 SEK
2012-05-30 - Årsstämma
2012-05-23 - Kvartalsrapport 2012-Q1
2012-02-16 - Bokslutskommuniké 2011
2011-11-24 - Kvartalsrapport 2011-Q3
2011-05-26 - X-dag ordinarie utdelning RAY B 0.50 SEK
2011-05-25 - Årsstämma
2011-05-04 - Kvartalsrapport 2011-Q1
2011-02-18 - Bokslutskommuniké 2010
2010-11-12 - Kvartalsrapport 2010-Q3
2010-08-27 - Kvartalsrapport 2010-Q2
2010-05-26 - X-dag ordinarie utdelning RAY B 0.50 SEK
2010-05-25 - Årsstämma
2010-05-11 - Kvartalsrapport 2010-Q1
2009-11-20 - Kvartalsrapport 2009-Q3
2009-08-27 - Kvartalsrapport 2009-Q2
2009-05-27 - X-dag ordinarie utdelning RAY B 0.00 SEK
2009-05-26 - Årsstämma
2009-05-15 - Kvartalsrapport 2009-Q1
2008-06-25 - Split RAY B 1:3
2003-06-10 - Split RAY B 20:1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
RaySearch Laboratories är verksamt inom medicinteknikbranschen och fokuserar på utveckling och tillverkning av mjukvara för strålbehandling av cancer. Bolagets produkter riktar sig till sjukvårdsinstitutioner och onkologer. Verksamheten är internationell och riktar sig till kunder globalt. Laboratories grundades 2000 och har sitt huvudkontor i Stockholm.
2021-08-25 07:45:00

"In the second quarter of 2021, net sales declined 6 percent due to lower license sales. Recurring support revenue rose 9 percent and accounted for 44 percent (38) of net sales. Operating loss amounted to SEK -22 M (-11)", says Johan Löf, CEO of RaySearch.

SECOND QUARTER (APRIL-JUNE 2021)
  • Order intake SEK 189.8 M (177.1)
  • Net sales SEK 154.6 M (163.8)
  • Operating loss SEK -22.5 M (-10.9)
  • Loss after tax SEK -16.5 M (-9.2)
  • Loss per share before/after dilution SEK -0.48 (-0.27)
  • Cash flow SEK -74.4 M (65.9)
  • Order backlog SEK 1,213.4 M (1,185.8) at the end of the period
FIRST HALF-YEAR (JANUARY-JUNE 2021)
  • Order intake SEK 334.9 M (477.2)
  • Net sales SEK 316.7 M (372.6)
  • Operating loss SEK -10.2 M (40.6)
  • Loss after tax SEK -9.4 M (31.3)
  • Loss per share before/after dilution SEK -0.27 (0.91)
  • Cash flow SEK -41.6 M (61.7)
SIGNIFICANT EVENTS DURING THE SECOND QUARTER
  • The RayStation® treatment planning system was sold to several leading cancer centers, including the Atrium Health Carolinas Medical Center and the Radiation Center of Greater Nashua in the US, the Institute de Cancerologie Jean Godinot in France, the German Oncology Center in Cyprus, and the Higashi Omi City Gamo Medical Center in Japan.
  • The Centre hospitalier universitaire vaudois (CHUV) has purchased the RayCare® oncology information system and the RayIntelligence® data analytics system, and also expanded its RayStation installation with functionality for automatic planning and segmentation with machine learning as well as planning for Accuray's CyberKnife® system.
  • In March 2021, RaySearch breached an EBITDA-based covenant in the company's credit facility with Skandinaviska Enskilda Banken (SEB) with a credit limit of SEK 350 M. As a consequence, the amount of credit withdrawn of SEK 50 M was repaid in April. Now the company meets the covenants and the credit facility is thus available for utilization.
  • RaySearch has signed a sales agent agreement with Canon Medical Systems USA, Inc., enabling RaySearch America's salesforce to promote Canon Medical's Aquilion Large Bore CT and Celesteion PET/CT products.
  • RayStation 11A was released in May, the latest version of RaySearch's treatment planning system, with support for Accuray's CyberKnife system, prescription of specific dose levels to multiple tumors, the use of multiple GPUs in Monte Carlo simulation for photons, and improved integration with RayCare and RayCommand.
  • RayCare 5A was released in May, the latest version of RaySearch's oncology information system, with support for Accuray's CyberKnife® system, radiation therapy prescriptions, a new whiteboard that provides an overview of patient treatments, configurable forms, and a number of enhancements to task management, scheduling and automation.
  • In June, RayStation 9 was granted regulatory clearance in China - a significant growth market for RaySearch.
THE COVID-19 PANDEMIC
  • The COVID-19 pandemic with temporary reprioritizations in healthcare continued to have a negative impact on sales in the second quarter. RaySearch expects that the negative effects of the COVID-19 pandemic on the company's sales and earnings will continue for some months to come, mainly because orders may be delayed.

NO SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

TELECONFERENCE IN CONJUNCTION WITH THE INTERIM REPORT

CEO Johan Löf and CFO Peter Thysell will present RaySearch's interim report for January-June 2021 at a teleconference to be held in English on Wednesday, August 25, 2021 at 4:00-4:30 p.m. CEST.

For login details to the teleconference, please register on:
http://emea.directeventreg.com/registration/3790384
 

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President and CEO                   Tel: +46 8 510 530 00              E-mail: johan.lof@raysearchlabs.com
Peter Thysell, CFO                                     Tel: +46 70 661 05 59              E-mail: peter.thysell@raysearchlabs.com

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on August 25, 2021 at 7:45 a.m. CEST.

ABOUT RAYSEARCH

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare*. In December 2020, the company also launched a new treatment control system, RayCommand*, as well as the data anlytics system, RayIntelligence*. RaySearch's software is currently used by more than 2,600 cancer centers in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed for trading on Nasdaq Stockholm since 2003.
More information about RaySearch is available at www.raysearchlabs.com.

[*] Marketing clearance is required in some markets.